OCUL
Ocular TherapeutixCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful label expansion or a material partnering/financing win extends runway, validates recurring revenue and margins, and pushes valuation toward the bull target (~+60% from the anchor).
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -8.3.
What can break
Regulatory setbacks, weak commercial adoption, or a dilutive financing round materially reduce per-share value, pushing the stock toward the bear target (>‑40% from the anchor).
Momentum
15
Value
41
Sentiment
98
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.61 · Bull $18.34 · Bear $6.88
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-05 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $26.31
Why
Momentum15 · Δ7d -12.5
Value41 · Δ7d +0.1
Sentiment98 · Δ7d -8.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
15
34% active weight
Current posture
7d trendSoftening
Δ7d
-12.5
Δ21d
-18.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
98
33% active weight
Current posture
7d trendSoftening
Δ7d
-8.3
Δ21d
+15.1
Why this grade
Composite grade C. Momentum 15.4 / Value 41.1 / Sentiment 98.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.96B
Beta
0.91
Shares Out
213.05M
P/E (TTM) · Derived
-6.5
P/S (TTM)
44.11
P/FCF (TTM) · Derived
-7.98
Rev YoY
-5.7%
EPS YoY
-72.7%
Gross Margin
+88.9%
Op Margin
-449.7%
Net Debt
-$323.6M
Current Ratio
7.85
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology